GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Foresee Pharmaceuticals Co 6576.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

73.90

+2.78%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 431.3m

FY2016FY2025

Net income

−TWD 883.2m

FY2016FY2025

Free cash flow

−TWD 857.7m

FY2016FY2025

Shareholders' equity

TWD 929.6m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 431.3mTWD 418.7mTWD 195.0mTWD 301.5mTWD 226.0mTWD 230.4mTWD 75.2mTWD 26.0mTWD 23.7m—
Gross profitTWD 294.2mTWD 239.8mTWD 114.0mTWD 276.0mTWD 175.1mTWD 173.4mTWD 57.9mTWD 12.1mTWD 14.9m—
Research and developmentTWD 975.1mTWD 1.17bnTWD 961.4mTWD 621.2mTWD 614.6mTWD 537.6mTWD 418.8mTWD 441.9mTWD 358.6mTWD 232.2m
Operating income−TWD 862.3m−TWD 1.08bn−TWD 985.8m−TWD 437.7m−TWD 527.3m−TWD 481.8m−TWD 470.1m−TWD 545.0m−TWD 443.0m−TWD 310.8m
Net income−TWD 883.2m−TWD 1.08bn−TWD 1.04bn−TWD 472.6m−TWD 569.3m−TWD 510.7m−TWD 487.2m−TWD 551.5m−TWD 443.5m−TWD 308.5m
Diluted earnings per share-5.61-7.95-7.63-4.00-4.84-4.37-4.78-6.03-5.35-4.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 1.31bnTWD 2.16bnTWD 1.86bnTWD 1.30bnTWD 1.64bnTWD 2.10bnTWD 1.01bnTWD 624.6mTWD 703.1mTWD 658.1m
Cash and short-term investments—————————TWD 508.6m
Total liabilitiesTWD 380.8mTWD 560.2mTWD 616.9mTWD 393.4mTWD 321.3mTWD 270.4mTWD 113.4mTWD 126.0mTWD 99.4mTWD 118.7m
Debt—TWD 260.3mTWD 228.3mTWD 41.3mTWD 16.6mTWD 109.4mTWD 12.6m———
Shareholders' equityTWD 929.6mTWD 1.60bnTWD 1.24bnTWD 910.6mTWD 1.32bnTWD 1.83bnTWD 895.9mTWD 498.6mTWD 603.7mTWD 539.4m
Shares outstanding158m136m136m118m118m117m102m91m83m76m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−TWD 842.2m−TWD 1.17bn−TWD 887.6m−TWD 233.2m−TWD 213.3m−TWD 674.8m−TWD 447.8m−TWD 462.4m−TWD 483.1m−TWD 263.0m
Capital spending−TWD 15.5m−TWD 156.0m−TWD 46.3m−TWD 58.1m−TWD 7.6m−TWD 28.2m−TWD 86.5m−TWD 14.1m−TWD 17.9m−TWD 18.2m
Free cash flow−TWD 857.7m−TWD 1.33bn−TWD 933.8m−TWD 291.3m−TWD 221.0m−TWD 703.0m−TWD 534.3m−TWD 476.5m−TWD 501.0m−TWD 281.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 181.7mTWD 80.3mTWD 52.2mTWD 157.0mTWD 111.6mTWD 110.5mTWD 140.5mTWD 80.1m
Gross profitTWD 138.4mTWD 40.6mTWD 35.1mTWD 152.1mTWD 33.9mTWD 73.2mTWD 121.8mTWD 33.6m
Operating income−TWD 105.7m−TWD 136.0m−TWD 134.6m−TWD 116.0m−TWD 325.9m−TWD 285.8m−TWD 488.1m−TWD 292.7m
Net income−TWD 123.8mTWD 406.9m−TWD 146.4m−TWD 114.3m−TWD 329.4m−TWD 293.1m−TWD 488.9m−TWD 308.3m
Diluted earnings per share-0.792.58-0.93-0.73-2.13-1.89-3.60-2.27
Cash from operationsTWD 27.0m−TWD 179.0m−TWD 136.0m−TWD 256.0m−TWD 157.0m−TWD 291.0m−TWD 656.0m−TWD 256.0m
Capital spending−TWD 2.0m−TWD 44.0m−TWD 3.0m−TWD 4.0m−TWD 6.0m−TWD 1.0m−TWD 4.0m−TWD 120.0m
Free cash flowTWD 25.0m−TWD 223.0m−TWD 139.0m−TWD 260.0m−TWD 163.0m−TWD 292.0m−TWD 660.0m−TWD 376.0m
Total assetsTWD 1.86bnTWD 1.94bnTWD 1.31bnTWD 1.57bnTWD 1.57bnTWD 1.71bnTWD 2.16bnTWD 1.46bn
DebtTWD 370.9mTWD 368.4m—TWD 89.2mTWD 90.4mTWD 91.7mTWD 92.9mTWD 94.2m
Shareholders' equityTWD 1.27bnTWD 1.39bnTWD 929.6mTWD 1.06bnTWD 971.8mTWD 1.33bnTWD 1.60bnTWD 704.1m

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin68.2%57.3%58.4%91.5%77.5%75.3%—
Operating margin-199.9%-257.9%-505.4%-145.2%-233.3%-209.1%—
Net margin-204.8%-258.2%-531.3%-156.8%-251.9%-221.6%—
Return on equity-95.0%-67.6%-83.3%-51.9%-43.1%-27.9%—
Return on assets-67.4%-50.1%-55.7%-36.2%-34.7%-24.3%—
Free cash flow yield—-9.5%-7.9%-1.9%-2.2%-7.0%—
Revenue growth3.0%114.7%-35.3%33.4%-1.9%206.4%—
Earnings growth-18.3%4.3%119.3%-17.0%11.5%4.8%—
Current ratio3.44x4.62x3.38x7.08x17.51x13.87x—
Debt to equity0.00x0.06x0.00x—0.00x0.03x0.00x
Equity ratio70.9%74.1%66.9%69.8%80.4%87.1%—
Interest coverage-154.90x-160.97x-346.01x-1088.88x-774.32x-482.30x—
R&D as a share of sales226.1%280.0%493.0%206.0%271.9%233.3%—
Buybacks as a share of market value—-0.1%-14.9%-0.5%-0.5%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.7%13.4%—
Operating income25.4%12.3%10.0%
Net income23.2%11.6%10.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin62.8%68.6%70.6%—
Operating margin-228.5%-250.0%-242.6%—
Net margin-231.1%-257.9%-252.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-14.4-9.8-12.6-22.9-24.7-20.5-12.2-9.2-12.0-16.9
Price to sales29.425.267.035.862.145.579.0195.8224.1—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.